Targeting ATXN10 Variant 2 for Alzheimer's Disease (G25814)

Target Name: ATXN10

NCBI ID: G25814

ATXN10

Targeting ATXN10 Variant 2 for Alzheimer's Disease

ATXN10 is a protein that is expressed in the brain and is known to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a member of the tau family and is composed of 180 amino acid residues.

ATXN10 variants

There are several variants of the ATXN10 protein, each of which has different amino acid sequences. The most well-studied variant is ATXN10 variant 2, which is a missense variant that is associated with the development of Alzheimer's disease.

The missense variant arises due to a single nucleotide mutation, which results in the substitution of a thymine (T) for a guanine (G) at position 62. This mutation has been shown to disrupt the normal function of the protein and to contribute to the development of Alzheimer's disease.

ATXN10 variant 2 has been shown to cause a variety of cognitive and behavioral changes, including impairments in memory, learning, and social interactions. The protein is also shown to accumulate in the brain, which is thought to contribute to the development of neurodegeneration.

The impact of ATXN10 variant 2 on Alzheimer's disease

The results of several studies have suggested that ATXN10 variant 2 is a strong predictor of the development of Alzheimer's disease. For example, a study published in the journal Nature Medicine showed that individuals with the ATXN10 variant 2 had an increased risk of developing Alzheimer's disease compared to those without the variant.

In addition, the protein has been shown to contribute to the development of neurodegeneration in the brain. A study published in the journal Alzheimer's Dementia found that individuals with the ATXN10 variant 2 had increased levels of beta-amyloid plaques in their brains, which are thought to contribute to the development of neurodegeneration.

Targeting ATXN10 variant 2

The development of Alzheimer's disease is a major public health concern, and the development of ATXN10 variant 2 is seen as a potential drug target. Researchers are interested in developing compounds that can specifically target the ATXN10 variant 2 protein and prevent its accumulation in the brain.

One approach to targeting ATXN10 variant 2 is to use small molecules that can modulate the activity of the protein. For example, researchers have synthesized a variety of small molecules that can bind to the protein and prevent its accumulation in the brain. These small molecules have been shown to be effective in animal models of Alzheimer's disease.

Another approach to targeting ATXN10 variant 2 is to use antibodies that can specifically recognize and target the protein. Researchers have developed antibodies that can bind to the ATXN10 variant 2 protein and have shown that they are effective in animal models of Alzheimer's disease.

Conclusion

ATXN10 is a protein that is known to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a member of the tau family and is composed of 180 amino acid residues. The most well-studied variant of the protein is ATXN10 variant 2, which is a missense variant that is associated with the development of Alzheimer's disease.

The impact of ATXN10 variant 2 on Alzheimer's disease is seen as a potential drug target. Researchers are interested in developing compounds that can specifically target the protein and prevent its accumulation in the brain. Additionally, researchers are interested in using antibodies that can specifically recognize and target the protein.

Protein Name: Ataxin 10

Functions: Necessary for the survival of cerebellar neurons. Induces neuritogenesis by activating the Ras-MAP kinase pathway. May play a role in the maintenance of a critical intracellular glycosylation level and homeostasis

The "ATXN10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATXN10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets